Phys.OrgReport highlights opportunities and risks associated with synthetic biology and bioengineeringPhys.OrgRapid developments in the field of synthetic biology and its associated tools and methods, including more widely available gene editing techni… Continue reading
Cancer Immunotherapy Possible for HIV-Positive PatientsSpecialty Pharmacy TimesThe results from a phase 1 clinical trial suggest that checkpoint inhibitors may be effective in HIV-positive patients with advanced cancer, a population previously excluded… Continue reading
Pharmaceutical ProcessingThe Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy researchEurekAlert (press release)CHAPEL HILL — UNC Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, was awarded a $600,… Continue reading
Nature.comImmunotherapy: Gut bacteria modulate responses to PD-1 blockadeNature.comFor a range of cancers, anti-PD-1 or anti-PD-L1 immunotherapy has greatly improved outcomes for a minority of patients; however, predicting responses to immunotherapy re… Continue reading
Nature.comImmunotherapy: Gut bacteria modulate responses to PD-1 blockadeNature.comFor a range of cancers, anti-PD-1 or anti-PD-L1 immunotherapy has greatly improved outcomes for a minority of patients; however, predicting responses to immunotherapy re… Continue reading
Nature.comImmunotherapy: Gut bacteria modulate responses to PD-1 blockadeNature.comFor a range of cancers, anti-PD-1 or anti-PD-L1 immunotherapy has greatly improved outcomes for a minority of patients; however, predicting responses to immunotherapy re… Continue reading
R & D MagazineRevolutionary Imaging Technique Uses CRISPR to Map DNA MutationsR & D MagazineDescribed in a study published today in the journal Nature Communications, this novel approach uses high-speed atomic force microscopy (AFM) combined with a … Continue reading
|
Voyager Recruits Patients for Phase 1 Trial Testing VY-AADC01 Gene Therapy Delivery
Parkinson’s News Today Voyager Therapeutics announced it’s recruiting participants for the company’s new Phase 1 clinical trial to test a new approach for their gene therapy VY-AADC01 in Parkinson’s disease patients. The company has also released updates to its ongoing Phase … |